Emboline Prevails in German Utility Model Infringement Action Against AorticLab
Emboline, Inc., a developer of next-generation embolic protection technology, announced that a German court has ruled in favor of the company in a utility model infringement action against AorticLab srl. The ruling from the Munich Regional Court pertained to German Utility Model DE 20 2016 009 224, titled "Embolism Prevention Device." The court found that AorticLab infringed multiple asserted claims, leading to an order for broad injunctive and related relief.
The judgment mandates that AorticLab cease offering, marketing, importing, using, and possessing the infringing products in Germany. Additionally, the company is required to provide information regarding its infringing activities, recall and remove infringing products from distribution channels, surrender products for destruction under specific conditions, and compensate Emboline for damages. The ruling is subject to the rights of appeal under German law.
This decision reaffirms Emboline's strategy of developing next-generation embolic protection technologies supported by a robust global intellectual property portfolio. The company views the ruling as a testament to the importance of innovation and adherence to intellectual property rights in advancing medical technology for healthcare providers and patients.
Scott Russell, President and Chief Executive Officer of Emboline, stated, "This court ruling underscores the strength of Emboline's intellectual property portfolio and validates the innovation that our team has worked tirelessly to develop. We have made substantial investments in creating differentiated embolic protection technology and building a comprehensive global patent portfolio. We take the protection of our intellectual property very seriously and will continue to enforce our intellectual property rights to safeguard our innovations, our customers, and the value we create to protect patients worldwide."
Emboline, Inc. is a privately held medical technology company based in Santa Cruz, California, focused on developing technologies designed to reduce embolic complications during transcatheter cardiovascular procedures. The company's primary product, the Emboliner® Embolic Protection System, is designed to provide full cerebral and systemic embolic protection by capturing and removing debris that may be released during structural heart interventions, preventing potential damage to the brain and other vital organs. The Emboliner® device is currently investigational and is not available for commercial sale.